These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37713805)

  • 1. Applications of oxetanes in drug discovery and medicinal chemistry.
    Huang G; Hucek D; Cierpicki T; Grembecka J
    Eur J Med Chem; 2023 Dec; 261():115802. PubMed ID: 37713805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxetanes in Drug Discovery Campaigns.
    Rojas JJ; Bull JA
    J Med Chem; 2023 Sep; 66(18):12697-12709. PubMed ID: 37676858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxetanes in drug discovery: structural and synthetic insights.
    Wuitschik G; Carreira EM; Wagner B; Fischer H; Parrilla I; Schuler F; Rogers-Evans M; Müller K
    J Med Chem; 2010 Apr; 53(8):3227-46. PubMed ID: 20349959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the synthesis, stability and conformation of 2-sulfonyl-oxetane fragments.
    Morgan KF; Hollingsworth IA; Bull JA
    Org Biomol Chem; 2015 May; 13(18):5265-72. PubMed ID: 25857425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxetane Substrates of Human Microsomal Epoxide Hydrolase.
    Toselli F; Fredenwall M; Svensson P; Li XQ; Johansson A; Weidolf L; Hayes MA
    Drug Metab Dispos; 2017 Aug; 45(8):966-973. PubMed ID: 28600384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxetanes: Recent Advances in Synthesis, Reactivity, and Medicinal Chemistry.
    Bull JA; Croft RA; Davis OA; Doran R; Morgan KF
    Chem Rev; 2016 Oct; 116(19):12150-12233. PubMed ID: 27631342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hip To Be Square: Oxetanes as Design Elements To Alter Metabolic Pathways.
    Toselli F; Fredenwall M; Svensson P; Li XQ; Johansson A; Weidolf L; Hayes MA
    J Med Chem; 2019 Aug; 62(16):7383-7399. PubMed ID: 31310524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxetanes as versatile elements in drug discovery and synthesis.
    Burkhard JA; Wuitschik G; Rogers-Evans M; Müller K; Carreira EM
    Angew Chem Int Ed Engl; 2010 Nov; 49(48):9052-67. PubMed ID: 21031377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trifluoromethyl Oxetanes: Synthesis and Evaluation as a tert-Butyl Isostere.
    Mukherjee P; Pettersson M; Dutra JK; Xie L; Am Ende CW
    ChemMedChem; 2017 Oct; 12(19):1574-1577. PubMed ID: 28815966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Site-Selective Modification of Proteins with Oxetanes.
    Boutureira O; Martínez-Sáez N; Brindle KM; Neves AA; Corzana F; Bernardes GJL
    Chemistry; 2017 May; 23(27):6483-6489. PubMed ID: 28261889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adventures in drug-like chemistry space: from oxetanes to spiroazetidines and beyond!
    Rogers-Evans M; Knust H; Plancher JM; Carreira EM; Wuitschik G; Burkhard J; Li DB; Guérot C
    Chimia (Aarau); 2014; 68(7-8):492-9. PubMed ID: 25437389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical Space Exploration of Oxetanes.
    Alves FRS; Couñago RM; Laufer S
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33147789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unusual Transformations of Strain-Heightened Oxetanes.
    An J; Riel LP; Howell AR
    Acc Chem Res; 2021 Oct; 54(20):3850-3862. PubMed ID: 34592094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and stability of oxetane analogs of thalidomide and lenalidomide.
    Burkhard JA; Wuitschik G; Plancher JM; Rogers-Evans M; Carreira EM
    Org Lett; 2013 Sep; 15(17):4312-5. PubMed ID: 23937240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral Dosing.
    Li D; Sloman DL; Achab A; Zhou H; McGowan MA; White C; Gibeau C; Zhang H; Pu Q; Bharathan I; Hopkins B; Liu K; Ferguson H; Fradera X; Lesburg CA; Martinot TA; Qi J; Song ZJ; Yin J; Zhang H; Song L; Wan B; DAddio S; Solban N; Miller JR; Zamlynny B; Bass A; Freeland E; Ykoruk B; Hilliard C; Ferraro J; Zhai J; Knemeyer I; Otte KM; Vincent S; Sciammetta N; Pasternak A; Bennett DJ; Han Y
    J Med Chem; 2022 Apr; 65(8):6001-6016. PubMed ID: 35239336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of diversely functionalised 2,2-disubstituted oxetanes: fragment motifs in new chemical space.
    Davis OA; Croft RA; Bull JA
    Chem Commun (Camb); 2015 Oct; 51(84):15446-9. PubMed ID: 26344367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-(Aryl-sulfonyl)oxetanes as designer 3-dimensional fragments for fragment screening: synthesis and strategies for functionalisation.
    Morgan KF; Hollingsworth IA; Bull JA
    Chem Commun (Camb); 2014 May; 50(40):5203-5. PubMed ID: 24175317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of di-, tri-, and tetrasubstituted oxetanes by rhodium-catalyzed O-H insertion and C-C bond-forming cyclization.
    Davis OA; Bull JA
    Angew Chem Int Ed Engl; 2014 Dec; 53(51):14230-4. PubMed ID: 25313894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atropisomerism in Drug Discovery: A Medicinal Chemistry Perspective Inspired by Atropisomeric Class I PI3K Inhibitors.
    Perreault S; Chandrasekhar J; Patel L
    Acc Chem Res; 2022 Sep; 55(18):2581-2593. PubMed ID: 36069734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Use of Conformational Restriction in Medicinal Chemistry.
    de Sena M Pinheiro P; Rodrigues DA; do Couto Maia R; Thota S; Fraga CAM
    Curr Top Med Chem; 2019; 19(19):1712-1733. PubMed ID: 31659944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.